MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 341143 | Name: Mivotilate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mivotilate is a biochemical.

Chemical Structure

Mivotilate
Mivotilate
CAS#130112-42-4

Theoretical Analysis

MedKoo Cat#: 341143

Name: Mivotilate

CAS#: 130112-42-4

Chemical Formula: C12H14N2O3S3

Exact Mass: 330.0167

Molecular Weight: 330.44

Elemental Analysis: C, 43.62; H, 4.27; N, 8.48; O, 14.53; S, 29.11

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Mivotilate; YH 439; YH-439; YH439
IUPAC/Chemical Name
Isopropyl 2-(1,3-dithietane-2-ylidine)-2-(N-(4-methyl-2-thiazol-2-yl)carbamoyl)acetate
InChi Key
WOUUWUGULFOVHG-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H14N2O3S3/c1-6(2)17-10(16)8(11-19-5-20-11)9(15)14-12-13-7(3)4-18-12/h4,6H,5H2,1-3H3,(H,13,14,15)
SMILES Code
C(\C(C(=O)Nc1scc(n1)C)=C1\SCS1)(=O)OC(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 330.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhang J, Gao Y, Qian S, Liu X, Zu H. Physicochemical and pharmacokinetic characterization of a spray-dried malotilate emulsion. Int J Pharm. 2011 Jul 29;414(1-2):186-92. doi: 10.1016/j.ijpharm.2011.05.032. Epub 2011 May 17. PubMed PMID: 21619915. 2: Tariciotti G, Festuccia F, Lauria V, Attili AF. [Drugs inhibiting the hepatic fibrogenesis]. Minerva Gastroenterol Dietol. 1998 Mar;44(1):23-42. Italian. PubMed PMID: 16495880. 3: Nøjgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U; EMALD Group. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol. 2003 Aug;39(2):179-86. PubMed PMID: 12873813. 4: Zheng QZ, Wang LM, Lou YJ. [Establishment of BCG combined LPS-induced hepatocyte immunotoxicity model to assess liver protective effects]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2002 Aug;31(6):419-423. Chinese. PubMed PMID: 12601856. 5: Liu Y, Chen H, Jiang Y. [Effect of tanshinone IIA on CCl4-induced liver fibrosis in rats]. Zhong Yao Cai. 2002 Jan;25(1):31-3. Chinese. PubMed PMID: 12583240. 6: Li X, Yang X, Wu P, Meng Y, Li S, Lai W. Gene-CYP11B2 expression in rat liver in hepatic fibrogenesis induced by CCl4. Chin Med J (Engl). 2001 Jan;114(1):64-8. PubMed PMID: 11779439. 7: Naveau S. [Acute alcoholic hepatitis: treatments]. Presse Med. 2001 Jun 9;30(20):1024-30. Review. French. PubMed PMID: 11433695. 8: Yang X, Li X, Wu P, Meng Y, Li S, Lai W. CYP11B2 expression in rat liver and the effect of spironolactone on hepatic fibrogenesis. Horm Res. 2000;53(6):288-93. PubMed PMID: 11146369. 9: Mojzis J, Hegedüsová R, Mirossay L. Role of mucus in ischemia/reperfusion-induced gastric mucosal injury in rats. Physiol Res. 2000;49(4):441-6. PubMed PMID: 11072804. 10: Shibata T, Nagayasu H, Hamada J, Konaka S, Hosokawa M, Kawano T, Kitajo H, Arisue M. Inhibitory effects of malotilate on in vitro invasion of lung endothelial cell monolayer by human oral squamous cell carcinoma cells. Tumour Biol. 2000 Sep-Oct;21(5):299-308. PubMed PMID: 10940826. 11: Mirossay L, Kohút A, Mojzis J. Effect of malotilate on ethanol-induced gastric mucosal damage in capsaicin-pretreated rats. Physiol Res. 1999;48(5):375-81. PubMed PMID: 10625227. 12: Ohgoda O, Sakai A, Koga H, Kanai K, Miyazaki T, Niwano Y. Fibroblast-migration in a wound model of ascorbic acid-supplemented three-dimensional culture system: the effects of cytokines and malotilate, a new wound healing stimulant, on cell-migration. J Dermatol Sci. 1998 Jun;17(2):123-31. PubMed PMID: 9673894. 13: Nagayasu H, Hamada J, Kawano T, Konaka S, Nakata D, Shibata T, Arisue M, Hosokawa M, Takeichi N, Moriuchi T. Inhibitory effects of malotilate on invasion and metastasis of rat mammary carcinoma cells by modifying the functions of vascular endothelial cells. Br J Cancer. 1998 May;77(9):1371-7. PubMed PMID: 9652751; PubMed Central PMCID: PMC2150200. 14: Møller S, Becker PU, Juul A, Skakkebaek NE, Christensen E. [Prognostic value of insulin-like growth factor I-IGF-I--and its binding protein IGFBP-3 in alcoholic liver disease]. Ugeskr Laeger. 1997 Jul 21;159(30):4636-40. Danish. PubMed PMID: 9245039. 15: Xu Q, Lu J, Wang R, Wu F, Cao J, Chen X. Liver injury model induced in mice by a cellular immunologic mechanism--study for use in immunopharmacological evaluations. Pharmacol Res. 1997 Apr;35(4):273-8. PubMed PMID: 9264042. 16: Choi EY, Kim SG, Lee JW, Yoo JK, Shin JK, Kim ND. Suppression of rat hepatic cytochrome P450 2E1 expression by isopropyl 2-(1,3-dithioetane-2-ylidene)-2-[N-(4-methyl-thiazol-2-yl)carbamoyl] acetate (YH439), an experimental hepatoprotectant: protective role against hepatic injury. Biochem Pharmacol. 1996 Oct 25;52(8):1219-25. PubMed PMID: 8937429. 17: Lee IJ, Jeong KS, Roberts BJ, Kallarakal AT, Fernandez-Salguero P, Gonzalez FJ, Song BJ. Transcriptional induction of the cytochrome P4501A1 gene by a thiazolium compound, YH439. Mol Pharmacol. 1996 Jun;49(6):980-8. PubMed PMID: 8649358. 18: Møller S, Becker U, Juul A, Skakkebaek NE, Christensen E. Prognostic value of insulinlike growth factor I and its binding protein in patients with alcohol-induced liver disease. EMALD group. Hepatology. 1996 May;23(5):1073-8. PubMed PMID: 8621136. 19: Niwano Y, Koga H, Sakai A, Kanai K, Hamaguchi H, Uchida M, Tachikawa T. Wound healing effect of malotilate in rats. Arzneimittelforschung. 1996 Apr;46(4):450-5. PubMed PMID: 8740099. 20: Ryhanen L, Stenback F, Ala-Kokko L, Savolainen ER. The effect of malotilate on type III and type IV collagen, laminin and fibronectin metabolism in dimethylnitrosamine-induced liver fibrosis in the rat. J Hepatol. 1996 Feb;24(2):238-45. PubMed PMID: 8907579.